Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunome (IMNM – Research Report), Viridian Therapeutics (VRDN – Research Report) and OmniAb (OABI – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immunome (IMNM)
Truist Financial analyst Karina Rabayeva maintained a Buy rating on Immunome today. The company’s shares closed last Monday at $22.64, close to its 52-week high of $25.75.
Rabayeva has an average return of
According to TipRanks.com, Rabayeva is ranked #8922 out of 10192 analysts.
Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $27.30, a 19.1% upside from current levels. In a report issued on December 4, Craig-Hallum also maintained a Buy rating on the stock with a $26.00 price target.
See today’s best-performing stocks on TipRanks >>
Viridian Therapeutics (VRDN)
Truist Financial analyst Gregory Renza maintained a Buy rating on Viridian Therapeutics today. The company’s shares closed last Monday at $33.03.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $40.77, representing a 21.1% upside. In a report issued on December 3, William Blair also initiated coverage with a Buy rating on the stock with a $47.00 price target.
OmniAb (OABI)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on OmniAb. The company’s shares closed last Monday at $2.03.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
OmniAb has an analyst consensus of Strong Buy, with a price target consensus of $6.75, representing a 211.1% upside. In a report released yesterday, Craig-Hallum also maintained a Buy rating on the stock.
